Editorial: Minimal residual disease in acute myeloid leukemia: Already predicting a safe haven?

Expert Review of Hematology

Volumn 3, Issue 1, 2010, Pages 1-5

  Schuurhuis, Gerrit Jan ^a   Ossenkoppele, Gert ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; WT1 PROTEIN; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; NUCLEAR PROTEIN; NUCLEOPHOSMIN; WTAP PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER STEM CELL; CHROMOSOME ABERRATION; DIAGNOSTIC VALUE; EDITORIAL; HUMAN; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; ALLOTRANSPLANTATION; CHILD; GENETICS; METABOLISM;

CHILD; FMS-LIKE TYROSINE KINASE 3; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; NUCLEAR PROTEINS; PROGNOSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 77953404187     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.69     Document Type: Editorial

References (31)

1. Bene MC, Kaeda JS. How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet. Haematologica 94(8), 1135-1150 (2009).
2. Schrappe M, Beier R, Burger B. New treatment strategies in childhood acute lymphoblastic leukaemia. Best. Pract. Res. Clin. Haematol. 15(4), 729-740 (2002).
3. Cazzaniga G, Biondi A. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica 90(3), 382-390 (2005).
4. Feller N, van der Pol MA, van Stijn A et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 18(8), 1380-1390 (2004).
5. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104(10), 3078-3085 (2004). (Pubitemid 39517010)
6. Langebrake C, Creutzig U, Dworzak M et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM study group. J. Clin. Oncol. 24(22), 3686-3692 (2006).
7. San Miguel JF, Martinez A, Macedo A et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 90(6), 2465-2470 (1997).
8. San Miguel JF, Vidriales MB, Lopez- Berges C et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98(6), 1746-1751 (2001).
9. Venditti A, Buccisano F, Del Poeta G et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 96(12), 3948-3952 (2000).
10. Sievers EL, Lange BJ, Alonzo TA et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 101(9), 3398-3406 (2003).
11. Maurillo L, Buccisano F, Del Principe MI et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J. Clin. Oncol. 26(30), 4944-4951 (2008).
12. Schnittger S, Kern W, Tschulik C et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 114(11), 2220-2231 (2009).
13. Dworzak MN, Gaipa G, Ratei R et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: multicentric assessment is feasible. Cytometry B Clin. Cytom. 74(6), 331-340 (2008).
14. Cloos J, Goemans BF, Hess CJ et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 20(7), 1217-1220 (2006).
15. Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 100(7), 2393-2398 (2002).
16. Bachas C, Schuurhuis GJ, Hollink IHIM et al. Frequent instability of type I and II aberrations between diagnosis and relapse observed in pediatric AML; implications for targeted therapy and MRD detection. Blood 114, 649 (2009).
17. Gorello P, Cazzaniga G, Alberti F et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 20(6), 1103-1108 (2006).
18. Chou WC, Tang JL, Wu SJ et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 21(5), 998-1004 (2007).
19. Kern W, Haferlach C, Bacher U, Haferlach T, Schnittger S. Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity. Leukemia 23(7), 1361-1364 (2009).
20. Cilloni D, Renneville A, Hermitte F et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J. Clin. Oncol. 27(31), 5195-5201 (2009).
21. Tajeddine N, Millard I, Gailly P, Gala JL. Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin. Chem. Lab. Med. 44(5), 548-555 (2006).
22. Steinbach D, Schramm A, Eggert A et al. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin. Cancer Res. 12(8), 2434-2441 (2006).
23. Pedreira CE, Costa ES, Barrena S et al. Generation of flow cytometry data files with a potentially infinite number of dimensions. Cytometry A 73(9), 834-846 (2008).
24. van der Velden VHJ, Jacobs DCH, Wijkhuijs AJM et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia 16(8), 1432-1436 (2002).
25. Maurillo L, Buccisano F, Spagnoli A et al. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica 92(5), 605-611 (2007).
26. Kern W, Haferlach T, Schoch C et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative group (AMLCG) 1992 Trial. Blood 101(1), 64-70 (2003).
27. van Rhenen A, Feller N, Kelder A et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin. Cancer Res. 11(18), 6520-6527 (2005).
28. Terwijn M, Kelder A, Rutten AP, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ. High leukemic cell frequency in remission bone marrow predicts poor outcome in acute myeloid leukemia. Blood 112, 881 (2008).
29. Terwijn M, Kelder A, Rutten AP et al. Specific flow cytometric detection of leukemic stem cells in acute myeloid leukemia predicts prognosis in remission bone marrow. Blood 114, 165 (2009).
30. Krause DS, Van Etten RA. Right on target: eradicating leukemic stem cells. Trends Mol. Med. 13(11), 470-481 (2007).
31. Majeti R, Chao MP, Alizadeh AA et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138(2), 286-299 (2009).